Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 168.1% in October

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 31,100 shares, an increase of 168.1% from the October 15th total of 11,600 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average daily trading volume, of 366,500 shares, the short-interest ratio is currently 0.1 days.

Altamira Therapeutics Stock Performance

CYTO opened at $0.43 on Friday. The company’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $1.03. Altamira Therapeutics has a 1-year low of $0.40 and a 1-year high of $17.20.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.